Corona Virus Infection — Trial of Hydroxychloroquine In Covid-19 Kinetics
Citation(s)
Baden LR, Rubin EJ Covid-19 - The Search for Effective Therapy. N Engl J Med. 2020 May 7;382(19):1851-1852. doi: 10.1056/NEJMe2005477. Epub 2020 Mar 18.
Baron SA, Devaux C, Colson P, Raoult D, Rolain JM Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020 Apr;55(4):105944. doi: 10.1016/j.ijantimicag.2020.105944. Epub 2020 Mar 13.
Chan KW, Wong VT, Tang SCW COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am J Chin Med. 2020;48(3):737-762. doi: 10.1142/S0192415X20500378. Epub 2020 Mar 13. Review.
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.
Cunningham AC, Goh HP, Koh D Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020 Mar 16;24(1):91. doi: 10.1186/s13054-020-2818-6.
Devaux CA, Rolain JM, Colson P, Raoult D New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.
Dong L, Hu S, Gao J Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.
Fedson DS, Opal SM, Rordam OM Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. mBio. 2020 Mar 20;11(2). pii: e00398-20. doi: 10.1128/mBio.00398-20.
FitzGerald GA Misguided drug advice for COVID-19. Science. 2020 Mar 27;367(6485):1434. doi: 10.1126/science.abb8034. Epub 2020 Mar 20.
Gao J, Tian Z, Yang X Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
Jiang S Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. 2020 Mar;579(7799):321. doi: 10.1038/d41586-020-00751-9.
Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, Yu W, Zhang J Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020 Jun;95:183-191. doi: 10.1016/j.ijid.2020.03.013. Epub 2020 Mar 12.
Lotery A, Burdon M Monitoring for hydroxychloroquine retinopathy. Eye (Lond). 2020 Aug;34(8):1301-1302. doi: 10.1038/s41433-020-0795-2. Epub 2020 Feb 13.
Percival I Nuclear winter. Practitioner. 1988 Feb 8;232(1442):140-1.
Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. Arthritis Rheumatol. 2020 Mar;72(3):448-453. doi: 10.1002/art.41121. Epub 2020 Jan 7.
Sahraei Z, Shabani M, Shokouhi S, Saffaei A Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020 Apr;55(4):105945. doi: 10.1016/j.ijantimicag.2020.105945. Epub 2020 Mar 17.
Sivakumar GK, Liu J, Sokoluk C, Ing EB Online calculator for hydroxychloroquine dosing. Can J Ophthalmol. 2020 Aug;55(4):e148-e150. doi: 10.1016/j.jcjo.2020.01.002. Epub 2020 Feb 18.
Sun ML, Yang JM, Sun YP, Su GH [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222. doi: 10.3760/cma.j.issn.1001-0939.2020.03.016. Chinese.
Sun Q, Qiu H, Huang M, Yang Y Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. Ann Intensive Care. 2020 Mar 18;10(1):33. doi: 10.1186/s13613-020-00650-2.
Zhou D, Dai SM, Tong Q COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. doi: 10.1093/jac/dkaa114.
A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.